Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
TREMFYA (Janssen Biotech, Inc.)
(https://tremfya.com) 📸 Data Snapshot: June 20, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Official Consumer Website for TREMFYA® (guselkumab) (https://tremfya.com)
Title
Official Consumer Website for TREMFYA® (guselkumab)
Meta
Learn about treatment with TREMFYA® (guselkumab) across all uses, including the support program, TREMFYA withMe, on the official patient website. See full Prescribing & Safety Info.
H1 Ready to learn how TREMFYA® could help you? Start by choosing a condition below.
H2 Learn about TREMFYA withMe
H3 A support program for patients who are prescribed TREMFYA®
HEADING_BODY Plaque Psoriasis (PsO) | TREMFYA® (guselkumab) (https://tremfya.com/plaque-psoriasis/)
Title
Plaque Psoriasis (PsO) | TREMFYA® (guselkumab)
Meta
Learn about TREMFYA® (guselkumab) and how it is used to treat plaque psoriasis (PsO). See full Prescribing & Safety Information.
H1 FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (PsO)Clearer skinIS POSSIBLE with Tremfya®
H2 Your journey starts here
H3 Have a TREMFYA® prescription?
H3 Looking to save on out-of-pocket costs?
HEADING_BODY Active Psoriatic Arthritis (PsA) Treatment | TREMFYA® (guselkumab) (https://tremfya.com/psoriatic-arthritis/)
Title
Active Psoriatic Arthritis (PsA) Treatment | TREMFYA® (guselkumab)
Meta
Discover TREMFYA® (guselkumab) as a treatment option for adults with active psoriatic arthritis (PsA). See full Prescribing & Safety Information.
H1 FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)Less joint pain, stiffness, and swellingIS POSSIBLEwith TREMFYA®
H2 Your journey starts here
H2 Want to learn more about TREMFYA®?
H2 Start getting personalized support
H3 Have a TREMFYA® prescription?
H3 Have a TREMFYA® prescription?
H3 Looking to save on out-of-pocket costs?
HEADING_BODY Moderately to Severely Active UC | TREMFYA® (guselkumab) (https://tremfya.com/ulcerative-colitis/)
Title
Moderately to Severely Active UC | TREMFYA® (guselkumab)
Meta
Learn about TREMFYA® (guselkumab) for adults with moderately to severely active ulcerative colitis (UC). See full Prescribing & Safety Information.
H1 For adults with moderately to severely active ulcerative colitis (UC).Break awaywith TREMFYA®
H2 Why choose TREMFYA®?
H2 TREMFYA® is the only IL-23 blocker for UC to offer self-administration from the start
H3 In clinical trials of patients who received TREMFYA® IV initial and SC maintenance dosing, TREMFYA® helped patients achieve:
H3 JUST PRESCRIBED TREMFYA®?
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE · THIN (https://tremfya.com) Official Consumer Website for TREMFYA® (guselkumab)
[H1] Ready to learn how TREMFYA® could help you? Start by choosing a condition below. Moderate to severe plaque psoriasisActive psoriatic arthritisModerately to severely active ulcerative colitisModerately to severely active Crohn’s disease [H2] Learn about TREMFYA withMe [H3] A support program for patients who are prescribed TREMFYA® Learn More [IMG: Nurse] Dedicated Nurse Guide**Nurse Guides do not provide medical advice. [IMG: Cost] Prescription and Cost Support [IMG: Treatment] Treatment SupportSign Up for SupportReturning Patient Sign-InPatient Sign-In
563 chars
SUB-PAGE (https://tremfya.com/plaque-psoriasis/) Plaque Psoriasis (PsO) | TREMFYA® (guselkumab)
FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (PsO) [IMG: millionminds-logo] [H1] FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (PsO)Clearer skin Explore resultsIn clinical studies, at least 7 out of 10 patients saw at least 90% clearer skin at 16 weeks. Results may vary.Next [H2] Your journey starts here Explore Results [IMG: Tremfya-with-me-logo] [H3] Have a TREMFYA® prescription? Get dedicated support from TREMFYA withMe.Sign Up for Support [H3] Looking to save on out-of-pocket costs? Explore Savings Options [IMG: Arrow] slide 1slide 2 [IMG: Arrow] The support and resources provided by TREMFYA withMe are not intended to give medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment. [IMG: Girl] [IMG: Girl] [IMG: TWM] Actor portrayalTREMFYA withMe Nurse Guides do not provide medical advice. Please ask your doctor any questions you might have about your disease and treatment. [IMG: Upwards arrow icon]
1008 chars
SUB-PAGE (https://tremfya.com/psoriatic-arthritis/) Active Psoriatic Arthritis (PsA) Treatment | TREMFYA® (guselkumab)
[IMG: Imagine being a million miles away] [IMG: Woman in a green dress leaning on a stone wall overlooking the coast] [IMG: Woman in a green dress leaning on a stone wall overlooking the coast] [IMG: Imagine being a million miles away] [H1] FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)Less joint pain, stiffness, and swellingIS POSSIBLEwith TREMFYA® Explore results [IMG: Woman in a green dress leaning on a stone wall overlooking the coast] [IMG: Woman in a green dress leaning on a stone wall overlooking the coast] Next [H2] Your journey starts here Explore Results [H3] Have a TREMFYA® prescription? [H3] Have a TREMFYA® prescription? Get dedicated support from TREMFYA withMe.Get dedicated support from TREMFYA withMe.Sign Up for Support [H3] Looking to save on out-of-pocket costs? Learn About Cost Support [IMG: Arrow] slide 1slide 2 [IMG: Arrow] The support and resources provided by TREMFYA withMe are not intended to give medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment. [IMG: TREMFYA withMe nurse guide] [IMG: Logo] [IMG: TWM] Actor portrayalTREMFYA withMe Nurse Guides do not provide medical advice. Please ask your doctor any questions you might have about your disease and treatment. [H2] Want to learn more about TREMFYA®? [H2] Start getting personalized support Sign Up for Updates [IMG: Upwards arrow icon]
1419 chars
SUB-PAGE (https://tremfya.com/ulcerative-colitis/) Moderately to Severely Active UC | TREMFYA® (guselkumab)
[IMG: Image of a male ulcerative colitis (UC) TREMFYA® patient happy to be camping in the great outdoors] [IMG: Image of a male ulcerative colitis (UC) TREMFYA® patient happy to be camping in the great outdoors] [H1] For adults with moderately to severely active ulcerative colitis (UC).Break awaywith TREMFYA® See howHow TREMFYA® worksSee the scienceHow TREMFYA® could helpSee the resultsHow to take TREMFYA®Discover dosing [H2] Why choose TREMFYA®? [H3] In clinical trials of patients who received TREMFYA® IV initial and SC maintenance dosing, TREMFYA® helped patients achieve: FAST ACTINGRapid symptom relief* at 4 weeks and clinical remission at week 12.*Symptom relief is based on fewer bowel movements and less rectal bleeding (bloody stools) observed as early as week 4.LONG LASTING Clinical remission at 1 year.††Results were measured in TREMFYA® patients who met clinical response at 12 weeks.VISIBLE REPAIR OF THE INTESTINAL LININGEndoscopic remission at 1 year.‡§‡Visually assessed areas may not represent remission of the entire colon lining.§Results were measured in TREMFYA® patients who met clinical response at 12 weeks.AT 2 YEARS,AT 2 YEARS,patients were in clinical remission.ǁǁIn UC, results at 1 and 2 years were measured in TREMFYA® patients who met clinical response at 12 weeks. After 1 year, patients and doctors knew TREMFYA® was used. This may have influenced results.Results may vary. Talk to your healthcare provider to see if TREMFYA® is right for you.See how [IMG: TREMFYA® PEN 200 mg/2 mL] [H2] TREMFYA® is the only IL-23 blocker for UC to offer self-administration from the start You and your healthcare provider will discuss how you start TREMFYA® for UC:Subcutaneous (SC) injections under the skin following training*ORIV infusions through a vein in the armExplore your options*If your healthcare provider decides that you or a caregiver may be able to give your injections of TREMFYA® at home, you should receive training on the right way to prepare and inject TREMFYA®. Do not try to inject yourself until you have been trained by your healthcare provider.IL=interleukin. [IMG: Mountain range beside a body of water] [IMG: Mountain range beside a body of water] [IMG: Mountain range beside a body of water] [H3] JUST PRESCRIBED TREMFYA®? Get the most out of treatment with personalized support.Sign up
2338 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
32Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /plaque-psoriasis/ | 12 | 0 |
| /psoriatic-arthritis/ | 10 | 0 |
| /ulcerative-colitis/ | 10 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.tremfya.com/",
"name": "Official Consumer Website for TREMFYA® (guselkumab)",
"headline": "Ready to learn how TREMFYA® could help you? Start by choosing a condition below.",
"description": "Learn about treatment with TREMFYA® (guselkumab) across all uses, including the support program, TREMFYA withMe, on the official patient website. See full Prescribing & Safety Info.",
"audience": {
"@type": "Audience",
"audienceType": "Patient"
},
"specialty": [
"https://schema.org/Dermatologic",
"Rheumatologic",
"Gastroenterologic"
],
"publisher": {
"@type": "Organization",
"name": "Janssen Biotech, Inc.",
"alternateName": "Johnson & Johnson",
"url": "https://innovativemedicine.jnj.com/",
"sameAs": "https://en.wikipedia.org/wiki/Janssen_Pharmaceuticals",
"logo": "https://static.innovativemedicine.jnj.com/d4/c2/3d888e9e401093d0d71efc503c63/innovative-medicine-logo-1.svg"
},
"about": [
{
"@type": "MedicalCondition",
"name": "plaque psoriasis"
},
{
"@type": "MedicalCondition",
"name": "psoriatic arthritis"
},
{
"@type": "MedicalCondition",
"name": "ulcerative colitis"
},
{
"@type": "MedicalCondition",
"name": "Crohn's disease"
},
{
"@type": "MedicalTherapy",
"adverseOutcome": [
{
"@type": "MedicalEntity",
"description": "The most common side effects of TREMFYA® include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, stomach pain, and bronchitis."
}
],
"seriousAdverseOutcome": [
{
"@type": "MedicalEntity",
"description": "TREMFYA® is a prescription medicine that may cause serious side effects, including: Serious Allergic Reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction: • fainting, dizziness, feeling lightheaded (low blood pressure) • swelling of your face, eyelids, lips, mouth, tongue or throat • trouble breathing or throat tightness • chest tightness • skin rash, hives • itching"
},
{
"@type": "MedicalEntity",
"description": "Infections. TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: • fever, sweats, or chills • muscle aches • weight loss • cough • warm, red, or painful skin or sores on your body different from your psoriasis • diarrhea or stomach pain • shortness of breath • blood in your phlegm (mucus) • burning when you urinate or urinating more often than normal"
},
{
"@type": "MedicalEntity",
"description": "Liver Problems. With the treatment of Crohn's disease or ulcerative colitis, your healthcare provider will do blood tests to check your liver before and during treatment with TREMFYA®. Your healthcare provider may stop treatment with TREMFYA® if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: • unexplained rash • vomiting • tiredness (fatigue) • yellowing of the skin or the whites of your eyes • nausea • stomach pain (abdominal) • loss of appetite • dark urine"
}
],
"recognizingAuthority": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration",
"alternateName": "FDA",
"url": "https://www.fda.gov/"
}
},
{
"@type": "Drug",
"name": "TREMFYA",
"nonProprietaryName": "guselkumab",
"activeIngredient": "guselkumab",
"prescribingInfo": "https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf",
"prescriptionStatus": "https://schema.org/PrescriptionOnly",
"dosageForm": [
"intravenous infusion",
"subcutaneous injection"
],
"administrationRoute": [
"intravenous",
"subcutaneous"
],
"doseSchedule": [
{
"@type": "DoseSchedule",
"doseUnit": "mg",
"doseValue": [
"100",
"200"
],
"description": "TREMFYA® is available as 100 mg/mL and 200 mg/2 mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.",
"targetPopulation": [
"adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light)",
"adults with active psoriatic arthritis",
"adults with moderately to severely active ulcerative colitis",
"adults with moderately to severely active Crohn’s disease"
]
}
],
"image": {
"@type": "ImageObject",
"name": "Tremfya logo",
"contentUrl": "https://www.tremfya.com/_next/static/media/tremfya-logo.3bdc0a3f.svg"
},
"manufacturer": {
"@type": "Organization",
"@id": "https://innovativemedicine.jnj.com/"
}
}
],
"mainContentOfPage": {
"@type": "WebPageElement",
"headline": "Learn about TREMFYA withMe",
"text": "A support program for patients who are prescribed TREMFYA®",
"potentialAction": [
{
"@type": "Action",
"name": "Sign Up for Support",
"url": "https://www.account1.jnjwithme.com/tremfya-withme/account/sign-up"
},
{
"@type": "Action",
"name": "Returning Patient Sign-In",
"url": "https://www.myjanssencarepath.com/services/auth/sso/OpenIdTremfya"
}
]
}
}
/plaque-psoriasis/
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.tremfya.com/plaque-psoriasis/",
"name": "Plaque Psoriasis (PsO) | TREMFYA® (guselkumab)",
"headline": "Living with moderate to severe plaque psoriasis? We're here for you.",
"description": "Learn about TREMFYA® (guselkumab) and how it is used to treat plaque psoriasis (PsO). See full Prescribing & Safety Information.",
"audience": {
"@type": "Audience",
"audienceType": "Patient"
},
"specialty": [
"https://schema.org/Dermatologic"
],
"publisher": {
"@type": "Organization",
"name": "Janssen Biotech, Inc.",
"alternateName": "Johnson & Johnson",
"url": "https://innovativemedicine.jnj.com/",
"sameAs": "https://en.wikipedia.org/wiki/Janssen_Pharmaceuticals",
"logo": "https://static.innovativemedicine.jnj.com/d4/c2/3d888e9e401093d0d71efc503c63/innovative-medicine-logo-1.svg"
},
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": {
"@id": "https://www.tremfya.com/",
"url": "https://www.tremfya.com/",
"name": "TREMFYA DTC Homepage"
}
},
{
"@type": "ListItem",
"position": 2,
"item": {
"@id": "https://www.tremfya.com/plaque-psoriasis/",
"url": "https://www.tremfya.com/plaque-psoriasis/",
"name": "TREMFYA plaque psoriasis"
}
}
]
},
"isPartOf": {
"@type": "WebSite",
"url": "https://www.tremfya.com/",
"name": "Official Consumer Website for TREMFYA® (guselkumab)",
"description": "Learn about treatment with TREMFYA® (guselkumab) across all uses, including the support program, TREMFYA withMe, on the official patient website. See full Prescribing & Safety Info.",
"inLanguage": "en-US",
"about": [
{
"@type": "MedicalCondition",
"name": "plaque psoriasis"
},
{
"@type": "MedicalTherapy",
"adverseOutcome": [
{
"@type": "MedicalEntity",
"description": "The most common side effects of TREMFYA® include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, stomach pain, and bronchitis."
}
],
"seriousAdverseOutcome": [
{
"@type": "MedicalEntity",
"description": "TREMFYA® is a prescription medicine that may cause serious side effects, including: Serious Allergic Reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction: • fainting, dizziness, feeling lightheaded (low blood pressure) • swelling of your face, eyelids, lips, mouth, tongue or throat • trouble breathing or throat tightness • chest tightness • skin rash, hives • itching"
},
{
"@type": "MedicalEntity",
"description": "Infections. TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: • fever, sweats, or chills • muscle aches • weight loss • cough • warm, red, or painful skin or sores on your body different from your psoriasis • diarrhea or stomach pain • shortness of breath • blood in your phlegm (mucus) • burning when you urinate or urinating more often than normal"
},
{
"@type": "MedicalEntity",
"description": "Liver problems. Your healthcare provider may stop treatment with TREMFYA® if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: • unexplained rash • vomiting • tiredness (fatigue) • yellowing of the skin or the whites of your eyes • nausea • stomach pain (abdominal) • loss of appetite • dark urine"
}
],
"recognizingAuthority": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration",
"alternateName": "FDA",
"url": "https://www.fda.gov/"
}
},
{
"@type": "Drug",
"name": "TREMFYA",
"nonProprietaryName": "guselkumab",
"activeIngredient": "guselkumab",
"prescribingInfo": "https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf",
"prescriptionStatus": "https://schema.org/PrescriptionOnly",
"dosageForm": "subcutaneous injection",
"administrationRoute": "subcutaneous",
"doseSchedule": [
{
"@type": "DoseSchedule",
"doseUnit": "mg",
"doseValue": "100",
"description": "TREMFYA® is available as a 100 mg/mL subcutaneous injection.",
"targetPopulation": "adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light)."
}
],
"image": {
"@type": "ImageObject",
"name": "TREMFYA® (guselkumab) logo",
"contentUrl": "https://www.tremfya.com/_next/static/media/tremfya-logo.3bdc0a3f.svg"
},
"manufacturer": {
"@type": "Organization",
"@id": "https://innovativemedicine.jnj.com/"
}
}
]
},
"mainContentOfPage": [
{
"@type": "WebPageElement",
"headline": "Want clearer skin with TREMFYA®?",
"potentialAction": {
"@type": "Action",
"name": "Find Out How",
"url": "https://www.tremfya.com/plaque-psoriasis/results/"
}
},
{
"@type": "WebPageElement",
"headline": "Have a TREMFYA® prescription?",
"text": "Get dedicated support from TREMFYA withMe.",
"potentialAction": {
"@type": "Action",
"name": "Sign Up for Support",
"url": "https://www.account1.jnjwithme.com/tremfya-withme/account/sign-up"
}
},
{
"@type": "WebPageElement",
"headline": "Looking to save on out-of-pocket costs?",
"potentialAction": {
"@type": "Action",
"name": "Explore Savings Options",
"url": "https://www.tremfya.com/plaque-psoriasis/savings-and-support/#prescription-support"
}
}
]
}
/psoriatic-arthritis/
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.tremfya.com/psoriatic-arthritis/",
"name": "Active Psoriatic Arthritis (PsA) Treatment | TREMFYA® (guselkumab)",
"headline": "For adults with active psoriatic arthritis.",
"description": "Learn about TREMFYA® (guselkumab) for the treatment of active psoriatic arthritis (PsA) in adults. See full Prescribing & Safety Information.",
"audience": {
"@type": "Audience",
"audienceType": "Patient"
},
"specialty": [
"https://schema.org/Dermatologic",
"https://schema.org/Rheumatologic"
],
"publisher": {
"@type": "Organization",
"name": "Janssen Biotech, Inc.",
"alternateName": "Johnson & Johnson",
"url": "https://innovativemedicine.jnj.com/",
"sameAs": "https://en.wikipedia.org/wiki/Janssen_Pharmaceuticals",
"logo": "https://static.innovativemedicine.jnj.com/d4/c2/3d888e9e401093d0d71efc503c63/innovative-medicine-logo-1.svg"
},
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": {
"@id": "https://www.tremfya.com/",
"url": "https://www.tremfya.com/",
"name": "TREMFYA® DTC Homepage"
}
},
{
"@type": "ListItem",
"position": 2,
"item": {
"@id": "https://www.tremfya.com/psoriatic-arthritis/",
"url": "https://www.tremfya.com/psoriatic-arthritis/",
"name": "TREMFYA® Psoriatic Arthritis"
}
}
]
},
"isPartOf": {
"@type": "WebSite",
"url": "https://www.tremfya.com/",
"name": "Official Consumer Website for TREMFYA® (guselkumab)",
"description": "Learn about treatment with TREMFYA® (guselkumab) across all uses, including the support program, TREMFYA withMe, on the official patient website. See full Prescribing & Safety Info.",
"inLanguage": "en-US",
"about": [
{
"@type": "MedicalCondition",
"name": "psoriatic arthritis"
},
{
"@type": "MedicalTherapy",
"adverseOutcome": [
{
"@type": "MedicalEntity",
"description": "The most common side effects of TREMFYA® include: respiratory tract infections, headache, injection-site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, stomach pain, and bronchitis."
}
],
"seriousAdverseOutcome": [
{
"@type": "MedicalEntity",
"description": "Serious Allergic Reactions: TREMFYA® may cause serious allergic reactions. Stop using TREMFYA® and get emergency medical help right away if you develop symptoms such as fainting, dizziness, swelling of your face, lips, mouth, tongue or throat, trouble breathing, chest tightness, skin rash, hives, or itching."
},
{
"@type": "MedicalEntity",
"description": "Infections: TREMFYA® may lower the ability of your immune system to fight infections. Contact your healthcare provider if you develop fever, sweats, chills, cough, shortness of breath, diarrhea, or painful skin sores."
},
{
"@type": "MedicalEntity",
"description": "Liver problems. Your healthcare provider may stop treatment with TREMFYA® if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: • unexplained rash • vomiting • nausea • tiredness • stomach pain • loss of appetite • yellowing of the skin or the whites of your eyes • dark urine."
}
],
"recognizingAuthority": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration",
"alternateName": "FDA",
"url": "https://www.fda.gov/"
}
},
{
"@type": "Drug",
"name": "TREMFYA",
"nonProprietaryName": "guselkumab",
"activeIngredient": "guselkumab",
"dosageForm": "Subcutaneous Injection",
"administrationRoute": "Subcutaneous Route",
"doseSchedule": [
{
"@type": "DoseSchedule",
"doseUnit": "mg",
"doseValue": 100,
"description": "TREMFYA® is available as a 100 mg/mL subcutaneous injection",
"targetPopulation": "adults with active psoriatic arthritis"
}
],
"image": {
"@type": "ImageObject",
"name": "Tremfya logo",
"contentUrl": "https://www.tremfya.com/_next/static/media/tremfya-logo.3bdc0a3f.svg"
},
"manufacturer": {
"@type": "Organization",
"@id": "https://innovativemedicine.jnj.com/"
}
}
]
}
}
/ulcerative-colitis/
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.tremfya.com/ulcerative-colitis/",
"name": "Moderately to Severely Active UC | TREMFYA® (guselkumab)",
"headline": "For adults with moderately to severely active ulcerative colitis (UC).",
"description": "Learn about TREMFYA® (guselkumab) for adults with moderately to severely active ulcerative colitis (UC). See full Prescribing & Safety Information.",
"audience": {
"@type": "Audience",
"audienceType": "Patient"
},
"specialty": [
"Gastroenterologic"
],
"publisher": {
"@type": "Organization",
"name": "Janssen Biotech, Inc.",
"alternateName": "Johnson & Johnson",
"url": "https://innovativemedicine.jnj.com/",
"sameAs": "https://en.wikipedia.org/wiki/Janssen_Pharmaceuticals",
"logo": "https://static.innovativemedicine.jnj.com/d4/c2/3d888e9e401093d0d71efc503c63/innovative-medicine-logo-1.svg"
},
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": {
"@id": "https://www.tremfya.com/",
"url": "https://www.tremfya.com/",
"name": "TREMFYA DTC Homepage"
}
},
{
"@type": "ListItem",
"position": 2,
"item": {
"@id": "https://www.tremfya.com/ulcerative-colitis/",
"url": "https://www.tremfya.com/ulcerative-colitis/",
"name": "TREMFYA ulcerative colitis"
}
}
]
},
"isPartOf": {
"@type": "WebSite",
"url": "https://www.tremfya.com/",
"name": "Official Consumer Website for TREMFYA® (guselkumab)",
"description": "Learn about treatment with TREMFYA® (guselkumab) across all uses, including the support program, TREMFYA withMe, on the official patient website. See full Prescribing & Safety Info.",
"inLanguage": "en-US",
"about": [
{
"@type": "MedicalCondition",
"name": "ulcerative colitis"
},
{
"@type": "MedicalTherapy",
"adverseOutcome": [
{
"@type": "MedicalEntity",
"description": "The most common side effects of TREMFYA® include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, stomach pain, and bronchitis."
}
],
"seriousAdverseOutcome": [
{
"@type": "MedicalEntity",
"description": "TREMFYA® is a prescription medicine that may cause serious side effects, including: Serious Allergic Reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction: • fainting, dizziness, feeling lightheaded (low blood pressure) • swelling of your face, eyelids, lips, mouth, tongue or throat • trouble breathing or throat tightness • chest tightness • skin rash, hives • itching"
},
{
"@type": "MedicalEntity",
"description": "Infections. TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: • fever, sweats, or chills • muscle aches • weight loss • cough • warm, red, or painful skin or sores on your body different from your psoriasis • diarrhea or stomach pain • shortness of breath • blood in your phlegm (mucus) • burning when you urinate or urinating more often than normal"
},
{
"@type": "MedicalEntity",
"description": "Liver Problems. With the treatment of Crohn's disease or ulcerative colitis, your healthcare provider will do blood tests to check your liver before and during treatment with TREMFYA®. Your healthcare provider may stop treatment with TREMFYA® if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: • unexplained rash • vomiting • tiredness (fatigue) • yellowing of the skin or the whites of your eyes • nausea • stomach pain (abdominal) • loss of appetite • dark urine"
}
],
"recognizingAuthority": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration",
"alternateName": "FDA",
"url": "https://www.fda.gov/"
}
},
{
"@type": "Drug",
"name": "TREMFYA",
"nonProprietaryName": "guselkumab",
"activeIngredient": "guselkumab",
"prescribingInfo": "https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf",
"prescriptionStatus": "https://schema.org/PrescriptionOnly",
"dosageForm": [
"intravenous infusion",
"subcutaneous injection"
],
"administrationRoute": [
"intravenous",
"subcutaneous"
],
"doseSchedule": [
{
"@type": "DoseSchedule",
"doseUnit": "mg",
"doseValue": [
"100",
"200"
],
"description": "TREMFYA® is available as 100 mg/mL and 200 mg/2 mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.",
"targetPopulation": "adults with moderately to severely active ulcerative colitis."
}
],
"image": {
"@type": "ImageObject",
"name": "Tremfya logo",
"contentUrl": "https://www.tremfya.com/_next/static/media/tremfya-logo.3bdc0a3f.svg"
},
"manufacturer": {
"@type": "Organization",
"@id": "https://innovativemedicine.jnj.com/"
}
}
]
},
"mainContentOfPage": [
{
"@type": "WebPageElement",
"headline": "Healing is possible* with TREMFYA®",
"text": "In clinical trials of patients who received TREMFYA®: 23% (200 mg IV) were in clinical remission at 12 weeks. 50% (200 mg SC) and 45% (100 mg SC) were in clinical remission at one year. *34% (200 mg SC) and 35% (100 mg SC) achieved endoscopic remission at one year. Visually assessed areas may not represent remission of the entire colon lining. Individual results may vary. IV=intravenous infusion; SC=subcutaneous injection.",
"potentialAction": {
"@type": "Action",
"name": "See How",
"url": "https://www.tremfya.com/ulcerative-colitis/results/"
}
},
{
"@type": "WebPageElement",
"headline": "How TREMFYA® works",
"potentialAction": {
"@type": "Action",
"name": "See the science",
"url": "https://www.tremfya.com/ulcerative-colitis/about-tremfya/"
}
},
{
"@type": "WebPageElement",
"headline": "How TREMFYA® could help",
"potentialAction": {
"@type": "Action",
"name": "See the results",
"url": "https://www.tremfya.com/ulcerative-colitis/results/"
}
},
{
"@type": "WebPageElement",
"headline": "How to take TREMFYA®",
"potentialAction": {
"@type": "Action",
"name": "Discover dosing",
"url": "https://www.tremfya.com/ulcerative-colitis/dosing/"
}
},
{
"@type": "WebPageElement",
"headline": "Why choose TREMFYA®?",
"text": "In clinical trials of patients who received TREMFYA® IV initial and SC maintenance dosing, TREMFYA® helped patients achieve:"
},
{
"@type": "WebPageElement",
"headline": "Fast acting",
"text": "Rapid symptom relief† at 4 weeks and clinical remission at week 12. †Symptom relief is based on fewer bowel movements and less rectal bleeding (bloody stools) observed as early as week 4."
},
{
"@type": "WebPageElement",
"headline": "Long lasting",
"text": "Clinical remission at 1 year."
},
{
"@type": "WebPageElement",
"headline": "Visible healing of the intestinal lining",
"text": "Endoscopic remission at 1 year.‡ ‡Visually assessed areas may not represent remission of the entire colon lining."
},
{
"@type": "WebPageElement",
"headline": "Results may vary. Talk to your healthcare provider to see if TREMFYA® is right for you.",
"potentialAction": {
"@type": "Action",
"name": "See how",
"url": "https://www.tremfya.com/ulcerative-colitis/results/"
}
},
{
"@type": "WebPageElement",
"headline": "TREMFYA® is the only IL-23 blocker for UC to offer self-administration from the start",
"text": "You and your healthcare provider will discuss how you start TREMFYA® for UC: Subcutaneous (SC) injections under the skin following training* OR IV infusions through a vein in the arm",
"potentialAction": {
"@type": "Action",
"name": "Explore your options",
"url": "https://www.tremfya.com/ulcerative-colitis/dosing/"
}
},
{
"@type": "WebPageElement",
"headline": "Just prescribed TREMFYA®?",
"text": "Get the most out of treatment with personalized support.",
"potentialAction": {
"@type": "Action",
"name": "Sign up",
"url": "https://www.account1.jnjwithme.com/tremfya-withme/account/sign-up/"
}
}
]
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
BS Detector
Medical Devices, Pharma & Biotech BS: TREMFYA (Janssen Biotech, Inc.) (tremfya.com)
https://tremfya.com
📍 Industry: Medical Devices, Pharma & Biotech
21
BS / 100
This site is a textbook example of high-substance pharmaceutical communication where regulatory oversight forces a low BS score. While it relies on weary marketing clichés and ‘ratings theatre,’ the core of the content is built on hard clinical data and technical specifications. It is a low-BS destination for patients, provided they look past the ‘Actor portrayal’ imagery to the raw trial percentages.
Info Density
Power-words vs. Substance ratio.
7
23% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
0
0% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
7
35% BS
Commodity Fingerprint
Detection of industry clichés/templates.
6
40% BS
Identity & Authority
Expert verifiability & Schema depth.
1
7% BS
Directly link the ‘clinical studies’ text to the published peer-reviewed journals or ClinicalTrials.gov identifiers to replace vague authority with forensic proof. Replace empty H2 slogans like ‘Your journey starts here’ with descriptive headers like ‘Dosing Options and Clinical Response Rates.’ Provide transparency for the review_count data by linking to a third-party review aggregator or a transparent internal methodology page. Finally, integrate Person schema for medical reviewers or the leadership team of the support program to close the ‘anonymous nurse’ authority gap.
The website perfectly aligns with the Pharma & Biotech industry, specifically focusing on Direct-to-Consumer (DTC) marketing for a prescription biologic. The content is heavily structured around therapeutic areas, clinical trial data, and regulatory safety requirements characteristic of FDA-monitored pharmaceutical products.
“The score was primarily driven by Trust Theatre (ratings without verified links) and Information Density (concept repetition and empty headers). The Commodity Fingerprint score reflects the standard pharma template usage, while the low Semantic Drift and high technical Authority kept the overall BS score within the 'Minimal BS' range.”
Verified Analysis Date: June 20, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from TREMFYA (Janssen Biotech, Inc.), captured on June 20, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to TREMFYA (Janssen Biotech, Inc.): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://tremfya.com to view the most current version of its content and learn from the source what this company is about and what it offers.